Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
Part of Cancer clinical trials.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have advanced liver cancer (Barcelona Clinic Liver Cancer stage C or stage B that cannot be treated with surgery or local treatments).
- Your cancer is confirmed by imaging, biopsy, or cell analysis.
- You have not had any prior systemic therapy (treatment that travels through your bloodstream) for liver cancer.
- You have at least one measurable tumor (can be seen on CT or MRI scans).
- Your liver function is good (Child-Pugh score 5-7) and your physical ability is fair (ECOG performance status 0-2).
- Your blood counts and organ function meet specific lab requirements (like enough white blood cells, platelets, and healthy liver and kidney function).
- You are willing to provide a sample of your tumor tissue (either from a past biopsy or a new one) and blood samples.
- You do not have active autoimmune disease needing strong immune-suppressing drugs, active serious infection, or uncontrolled hepatitis B or C.
- You do not have cancer that has spread to the brain and is causing symptoms.
- You are not pregnant or breastfeeding.
- You can follow the study procedures as determined by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well immune checkpoint inhibitors, which help the body's immune system fight cancer, work in people with advanced liver cancer. The goal is to see if these drugs are effective and safe for patients whose liver is still working reasonably well.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.